MOTS-c
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A mitochondria-derived peptide that activates AMPK signaling, marketed for metabolic health, fat loss, and exercise capacity. Its best-supported effects, better glucose handling and exercise capacity, come mostly from animal and mechanistic data; native MOTS-c has never been tested in a controlled human trial, so the human case is unproven. Most commercial supply is research-grade, with purity reported as low as 60 percent. Not approved in the US.
Read Full recordStudied uses & evidence
Studied uses(8)
Improved insulin sensitivity and glucose metabolism
MediumConsistent animal data and an AMPK/GLUT4 mechanism; one small human analog trial showed lower glucose.
Reduced obesity and fat accumulation
LowStrong animal weight and liver-fat data; the human analog trial showed no drug-versus-placebo benefit.
Enhanced physical performance and exercise capacity
MediumExtensive animal data shows better running capacity; no human performance trial yet.
Evidence limits
- Evidence Level
- Preclinical
Over 95% of MOTS-c evidence comes from cell culture and animal (primarily mouse) studies. Human data consists of observational/correlational studies measuring endogenous MOTS-c levels, a few exercise intervention studies measuring MOTS-c as a biomarker (not administering it), and one Phase 1a/1b trial of the analog CB4211 enrolling 88 subjects: 65 healthy participants and 23 participants with obesity and NAFLD, of whom 20 completed the Phase 1b assessments. No human trials have directly tested native MOTS-c injection for any therapeutic purpose. The preclinical evidence is robust and consistent across multiple disease models, but clinical translation remains in very early stages.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Hypoglycemia-prone individuals
ModerateMOTS-c enhances glucose uptake. May cause hypoglycemia in combination with insulin or sulfonylureas.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Native MOTS-c never given to humans in a controlled clinical trial
HighMost commercial MOTS-c is research-grade (purity as low as 60%)
HighEnhances glucose uptake; hypoglycemia risk with diabetes meds
ModerateInjection site reactions (CB4211 analog Phase 1)
LowAnecdotal palpitations and elevated heart rate
LowNausea, bloating, mild diarrhea (user reports)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.